Titus Daniels, MD, MPH, MMHC, has returned to Vanderbilt University Medical Center; he was previously on the faculty from 2007 to 2017.

Under the SARS CoV-2 Return to School Saliva Opt-in Screening Study, which began last November at University School of Nashville, a research team from Vanderbilt University Medical Center is testing a solution for efficient asymptomatic disease surveillance and control.

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.

The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.

Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have received renewal of a major federal grant to continue their collaboration to test and develop new treatments and vaccines against HIV/AIDS — and now COVID-19.

Health care workers, who have been disproportionately affected by the COVID-19 pandemic, will be the first tier of Vanderbilt University Medical Center employees to receive vaccine to prevent SARS-CoV-2 infection.